Response To Oral Agents in Diabetes (ROAD)- Pilot Study

University of Dundee

Status and phase: Completed; Phase 4

Conditions: Diabetes Mellitus, Type 2

Treatments: Drug: Sitagliptin; Drug: Gliclazide MR; Drug: Pioglitazone; Drug: Metformin

Study type: Interventional

Funder types: Other

Identifiers

NCT00780715

2008DM05

EudraCT 2008-004790-18

Details and patient eligibility

About

This proposal is to fund a pilot study to assess feasibility and refine methodology for an intended large Scotland wide study on Response to Oral Agents in Diabetes (ROAD). The study will collect cohorts of patients who have carefully controlled standardised dose titration and monitoring with an assessment of drug response and side effects over a 6 month period. The primary aim will be to use these cohorts to investigate phenotypic and genotypic (pharmacogenetic) determinants of response.

Drug naïve patients will be treated with Metformin. Patients who have failed on Metformin or are intolerant of Metformin will be randomised to gliclazide, pioglitazone or sitagliptin. With the ability to capture patient data beyond 6 months via data linkage we will monitor time to treatment failure and therefore compare which of the 3 oral agents is the best therapy to use after Metformin in a cost efficient and "real world" RCT.

Full description

The Response to Oral Agents in Diabetes (ROAD) study aims to address the limitations of observational data by creating a prospective study of incident users of oral agents. For the first six months the research team will ensure a protocol driven dose titration, standardised monitoring of adherence, response and side effects and standardised deviations from therapy. Thereafter patients will receive 6 monthly monitoring and further protocol led dose titration by the GP. Biochemistry, prescribing data, morbidity and mortality data will be captured for up to 10 years from drug initiation. The ROAD study will provide a highly powered prospective cohort to investigate phenotypic and genotypic determinants of response in its own right. However, this cohort will be used synergistically with ongoing observational pharmacogenetics studies, allowing for crucial replication of 'positive' signals. Furthermore, by randomisation at drug initiation, long term community follow up will allow a comparison of time to treatment failure in patients treated with gliclazide, pioglitazone and sitagliptin in a much more cost effective and 'real-world' setting than traditional prospective randomised trials This pilot study is to assess the feasibility of the larger complex intervention. The primary outcome of the pilot is HbA1c change. Other measures regarding recruitment and dose titration will be assessed. With knowledge from this pilot, an application will be made for a large region or Scotland wide study to collect 2000 patients incident to oral diabetes treatment.

Enrollment: 29 patients

Sex: All

Ages: 36 to 79 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Cohort 1 - metformin treatment

  • Type 2 diabetes diagnosed more than 6 weeks prior to visit 1
  • GP considers adequate diet and lifestyle advice given
  • Age >35 and < 80
  • Age of diabetes diagnosis >35
  • White European
  • HbA1c >7% & <=9%
  • eGFR>=50 ml/min
  • ALT <= 2.5*ULN
  • Contactable by telephone

• Cohort 2 - 2nd line treatment

  • Type 2 diabetes
  • Treated with metformin for more than 3 months; or metformin intolerant
  • Age >35 and < 80
  • Age of diabetes diagnosis >35
  • White European
  • HbA1c >7% & <=9%
  • eGFR>=50 ml/min
  • ALT <= 2.5*ULN
  • No previous history of heart failure; No patients with documented evidence of left ventricular systolic dysfunction OR with symptoms and signs consistent with a clinical diagnosis of heart failure
  • No treatment with Gemfibrozil or Rifampicin (CYP2C8 inhibitor or inducer respectively); or with Miconazole or phenylbutazone (increased hypoglycemic effect of gliclazide).
  • No diagnosis of osteoporosis
  • Contactable by telephone

Exclusion criteria

• Cohort 1

  • Type 1 diabetes
  • HbA1c >9% or <=7%
  • eGFR<50 ml/min
  • ALT > 2.5*ULN
  • Alcohol consumption in excess of 50 units per week
  • Pregnancy, lactation or a female planning to conceive within the study period
  • Any other significant medical reason for exclusion as determined by the investigator

• Cohort 2

  • Type 1 diabetes
  • HbA1c >9% or <=7%
  • eGFR< 50 ml/min
  • ALT > 2.5*ULN
  • Previous history of heart failure OR documented evidence of left ventricular systolic dysfunction OR symptoms and signs consistent with a clinical diagnosis of heart failure
  • Ongoing treatment with Gemfibrozil or Rifampicin (CYP2C8 inhibitor or inducer respectively); or with Miconazole or phenylbutazone (increased hypoglycemic effect of gliclazide).
  • Previous diagnosis of osteoporosis
  • Pregnancy, lactation or a female planning to conceive within the study period
  • Any other significant medical reason for exclusion as determined by the investigator

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

29 participants in 4 patient groups

Gliclazide MR

Active Comparator group

Treatment:

Drug: Gliclazide MR

Sitagliptin

Active Comparator group

Treatment:

Drug: Sitagliptin

Pioglitazone

Active Comparator group

Treatment:

Drug: Pioglitazone

Metformin

Experimental group

Treatment:

Drug: Metformin